Raymond Hohl

University Professor of Oncology; Professor of Pharmacology

Raymond Hohl

Publication Tags

Therapeutics Neoplasms Farnesyltranstransferase Acute Myeloid Leukemia Prenylation Glioblastoma Geranylgeranyl Pyrophosphate Biological Products Proteins Digeranyl Bisphosphonate T Lymphocytes Prostatic Neoplasms Growth Inhibitors Tipifarnib Cells Schweinfurthin F Terpenes Cell Line Biosynthetic Pathways Radiation Protein Prenylation Clinical Trials Dimethylallyltranstransferase Pharmacology Brain

Most Recent Papers

First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma

Bryan G. Allen, Kellie L. Bodeker, Mark C. Smith, Varun Monga, Sonia Sandhu, Raymond Hohl, Thomas Carlisle, Heather Brown, Nancy Hollenbeck, Sandy Vollstedt, Jeremy D. Greenlee, Matthew A. Howard, Kranti A. Mapuskar, Steven N. Seyedin, Joseph M. Caster, Karra A. Jones, Joseph J. Cullen, Daniel Berg, Brett A. Wagner, Garry R. Buettner, Mindi J. TenNapel, Brian J. Smith, Douglas R. Spitz, John M. Buatti, 2019, Clinical Cancer Research on p. 6590-6597

Increased flux through the mevalonate pathway mediates fibrotic repair without injury

Jennifer L. Larson-Casey, Mudit Vaid, Linlin Gu, Chao He, Guo Qiang Cai, Qiang Ding, Dana Davis, Taylor F. Berryhill, Landon S. Wilson, Stephen Barnes, Jeffrey D. Neighbors, Raymond J. Hohl, Kurt A. Zimmerman, Bradley K. Yoder, Ana Leda F. Longhini, Vidya Sagar Hanumanthu, Ranu Surolia, Veena B. Antony, A. Brent Carter, 2019, Journal of Clinical Investigation on p. 4962-4978

Eomes<sup>+</sup>T-bet<sup>low</sup> CD8<sup>+</sup> T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia

Bei Jia, Chenchen Zhao, Kevin L. Rakszawski, David Claxton, W. Christopher Ehmann, Witold Rybka, Shin Mineishi, Ming Wang, Hiroko Shike, Michael Bayerl, Jeffrey M. Sivik, Todd Schell, Joseph Drabick, Raymond Hohl, Hong Zheng, 2019, Cancer Research on p. 1635-1645

Brain cholesterol metabolism and Parkinson's disease

Xuemei Huang, Nicholas W. Sterling, Guangwei Du, Dongxiao Sun, Christina Stetter, Lan Kong, Yusheng Zhu, Jeffrey Neighbors, Mechelle Lewis, Honglei Chen, Raymond Hohl, Richard Mailman, 2019, Movement Disorders on p. 386-395

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity

Kathleen M. Kokolus, Jeremy S. Haley, Emily J. Koubek, Raghavendra Gowda, Saketh S. Dinavahi, Arati Sharma, David F. Claxton, Klaus F. Helm, Joseph J. Drabick, Gavin P. Robertson, Jeffrey D. Neighbors, Raymond J. Hohl, Todd D. Schell, 2019, OncoImmunology

The Dopamine D<sub>2</sub> Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells

Jillian S. Weissenrieder, Jessie L. Reed, Michelle V. Green, George Lucian Moldovan, Emily J. Koubek, Jeffrey D. Neighbors, Raymond J. Hohl, 2019, Pharmacology

Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models

Jillian S. Weissenrieder, Jacqueline E. Reilly, Jeffrey D. Neighbors, Raymond J. Hohl, 2019, Prostate on p. 21-30

Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML

Chenchen Zhao, Bei Jia, Ming Wang, Todd D. Schell, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Jeff M. Sivik, Raymond J. Hohl, Hui Zeng, Hong Zheng, 2019, British Journal of Haematology

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Liru Wang, Bei Jia, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng, 2018, OncoImmunology

Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis

Jacqueline E. Reilly, Jeffrey D. Neighbors, Raymond J. Hohl, 2017, Cancer Biology and Therapy on p. 872-882

Most-Cited Papers

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

A. Gronchi, B. N. Bui, S. Bonvalot, S. Pilotti, S. Ferrari, P. Hohenberger, R. J. Hohl, G. D. Demetri, A. Le cesne, P. Lardelli, I. Pérez, A. Nieto, J. C. Tercero, V. Alfaro, E. Tamborini, J. Y. Blay, 2012, Annals of Oncology on p. 771-776

O<sub>2</sub><sup>⋅−</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P. Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Shultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 487-500.e8

Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate

Brian M. Wasko, Amel Dudakovic, Raymond J. Hohl, 2011, Journal of Pharmacology and Experimental Therapeutics on p. 540-546

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients

Edward Messing, Jason R. Gee, Daniel R. Saltzstein, Kyung Mann Kim, Anthony DiSant'Agnese, Jill Kolesar, Linda Harris, Adrienne Faerber, Thomas Havighurst, Jay M. Young, Mitchell Efros, Robert H. Getzenberg, Marcia A. Wheeler, Joseph Tangrea, Howard Parnes, Margaret House, J. Erik Busby, Raymond Hohl, Howard Bailey, 2012, Cancer Prevention Research on p. 621-630

Geranylgeranyl diphosphate synthase

A. J. Wiemer, D. F. Wiemer, Raymond Hohl, 2011, Clinical pharmacology and therapeutics on p. 804-812

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Thomas E. Witzig, Hui Tang, Ivana N.M. Micallef, Stephen M. Ansell, Brian K. Link, David J. Inwards, Luis F. Porrata, Patrick B. Johnston, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Carrie A. Thompson, Cristine Allmer, Matthew J. Maurer, Mamta Gupta, George Weiner, Ray Hohl, Paul J. Kurtin, Husheng Ding, David Loegering, Paula Schneider, Kevin Peterson, Thomas M. Habermann, Scott H. Kaufmann, 2011, Blood on p. 4882-4889

Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells

Sarah A. Holstein, Raymond Hohl, 2011, Leukemia Research on p. 551-559

Is there a future for prenyltransferase inhibitors in cancer therapy?

Sarah A. Holstein, Raymond J. Hohl, 2012, Current Opinion in Pharmacology on p. 704-709

Structural analogues of schweinfurthin F

Natalie C. Ulrich, John G. Kodet, Nolan R. Mente, Craig H. Kuder, John A. Beutler, Raymond Hohl, David F. Wiemer, 2010, Bioorganic and Medicinal Chemistry on p. 1676-1683

Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration

Amel Dudakovic, Huaxiang Tong, Raymond J. Hohl, 2011, Investigational New Drugs on p. 912-920